Rajiv Shah and Tom Bumol Join PanTheryx Board of Directors as Biotech Expands Pipeline Candidates with Substantial R&D Investment

BOULDER, Colo.–(BUSINESS WIRE)–PanTheryx, a biotechnology company focused on addressing serious GI
related health conditions, announced today the appointment of Dr. Rajiv
Shah, MD, president of the Rockefeller Foundation, and Dr. Tom Bumol,
PhD, executive director of the Allen Institute for Immunology, to its
board of directors.

The addition of these two new members caps a pivotal year for PanTheryx,
as its products gained traction in commercial markets and R&D activities
continued to advance the company’s medical foods and biologics pipeline.
“2018 was an excellent year — our flagship product, DiaResQ®,
is helping children and adults worldwide with distribution agreements
covering over 50 countries, along with a U.S. retail distribution
footprint of over 25,000 stores,” said Mark Braman, CEO of PanTheryx.
“It’s an exciting time because we’re only in the beginning stages of
realizing the full potential of our patented technology platform. With
the successes we’ve seen in our pre-clinical models, we’re significantly
increasing our R&D investment to advance our pipeline.” As new members
to the board of directors, Dr. Shah and Dr. Bumol will help guide the
company’s efforts in the development of product candidates, including
those with the potential to impact public health globally.

With immunology being a core component of PanTheryx’s development
platform, Dr. Bumol’s expertise will help PanTheryx bring novel
innovations to market, with distinct mechanisms of action that target
the underlying etiology of challenging disease states. “I’m joining
PanTheryx at an exciting time in its evolution,” said Dr. Bumol. “I look
forward to helping the company further apply its technology within the
nexus of the most promising frontiers in medicine: immunology, gut
health, and the human microbiome.”

Before joining the Allen Institute, Dr. Bumol was the senior
vice-president of the Biotechnology and Immunology Research component at
Lilly Research Laboratories. He was also the site head of Lilly’s
Biotechnology Center of San Diego, which included the former Applied
Molecular Evolution subsidiary of Lilly Research Laboratories. Dr. Bumol
has over 50 publications and reviews, 8 issued U.S. patents, and his
team and collaborators have nominated over 100 molecules into clinical
development.

With multiple candidates poised to launch out of the R&D pipeline, Dr.
Shah has joined as vice-chair of the PanTheryx board of directors and
will help the company further its mission of providing education,
prevention, and care to the most at-risk populations in the world. “I am
excited about PanTheryx’s commitment to harnessing the power of science,
innovation and novel technologies to improve the lives of millions of
children and families around the world, particularly those with the
greatest needs.”

Dr. Shah brings over two decades of experience in business, government,
and philanthropy to his board director position. Before joining the
Rockefeller Foundation, Dr. Shah worked as the USAID administrator,
reshaping the agency’s operations to provide greater assistance to
pressing development challenges around the globe. In addition to
pioneering new public-private partnerships and scientific innovation, he
also led the U.S. government’s humanitarian response to crises around
the world, including the Haiti earthquake, Typhoon Haiyan and the Ebola
epidemic in Western Africa. Prior to that, he spent eight years at the
Bill and Melinda Gates Foundation where he led efforts in global health,
agriculture, and financial services.

About PanTheryx

PanTheryx is a biotechnology company committed to realizing the
potential of novel interventions to address a wide range of serious GI
microbiome related health conditions. The company is also the premier
supplier of bovine colostrum, and leverages its vertical integration to
develop and commercialize first-in-class therapeutics, with products
developed from its patented technology platform spanning the range of
nutritional interventions to biologics. Founded in 2007, PanTheryx is
headquartered in Boulder, Colorado and has production facilities in
Phoenix, AZ and Ripon, CA.

For more information, please visit www.PanTheryx.com.

Contacts

PanTheryx
Jess Teilborg – Vice President, Marketing
(720)
417-7325
[email protected]